Cerity Partners LLC Purchases 20,926 Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN)

Cerity Partners LLC boosted its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 207.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 31,020 shares of the medical equipment provider's stock after buying an additional 20,926 shares during the period. Cerity Partners LLC's holdings in Smith & Nephew SNATS were worth $880,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Callan Capital LLC bought a new position in Smith & Nephew SNATS during the first quarter valued at about $260,000. Envestnet Asset Management Inc. boosted its position in Smith & Nephew SNATS by 15.6% during the first quarter. Envestnet Asset Management Inc. now owns 618,691 shares of the medical equipment provider's stock worth $17,552,000 after purchasing an additional 83,341 shares during the period. Hexagon Capital Partners LLC boosted its position in shares of Smith & Nephew SNATS by 63.3% in the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock valued at $30,000 after acquiring an additional 406 shares during the period. Allspring Global Investments Holdings LLC bought a new position in shares of Smith & Nephew SNATS in the first quarter valued at approximately $335,000. Finally, Sequoia Financial Advisors LLC purchased a new stake in Smith & Nephew SNATS in the first quarter valued at approximately $211,000. Institutional investors and hedge funds own 25.64% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on SNN shares. Hsbc Global Res downgraded shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Canaccord Genuity Group lifted their price target on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a "hold" rating in a research note on Thursday, May 1st. Finally, HSBC downgraded shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Six research analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $28.00.

Smith & Nephew SNATS Stock Up 0.6%

Shares of SNN stock traded up $0.19 during mid-day trading on Friday, reaching $31.67. 514,702 shares of the company's stock traded hands, compared to its average volume of 1,069,158. Smith & Nephew SNATS, Inc. has a 12 month low of $23.69 and a 12 month high of $31.84. The company has a market cap of $13.87 billion, a P/E ratio of 14.66, a P/E/G ratio of 0.97 and a beta of 0.69. The company has a quick ratio of 1.33, a current ratio of 2.89 and a debt-to-equity ratio of 0.62. The company's 50-day moving average price is $29.75 and its 200-day moving average price is $27.90.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.